- nextellis deal is done dusted. mithra became a major SH with a seat on BoD. Mayne will continue to invest in this. only option for SH is to hope for the best. - why Mayne has so many scientists? doesn't makes sense for a company which was so heavily geared in generics space. some other generics companies also has R&D but are quite transparent on R&D investments. don't see that transparency in Mayne - although there was some restructure in FY22 in R&D team and intention to reduce in house R&D activities. - Salisbury- don't see why Mayne invest in manufacturing in Australia. look at the margin for that plant in SA. Perhaps strategic review of offloading that plant would be on table- only way Australian pharmaceutical manufacturing can compete in global markets are through high automation. the plant in SA is probably as old as some of those directors. - Mayne gets >80% revenue from US. all ducks are lining up to make key source of capital funding and commercial success in US.
DYOR IMO only
MYX Price at posting:
26.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)